Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pritumumab

Drug Profile

Pritumumab

Alternative Names: ACA 11; CLN-IgG; CLNH 11; Monoclonal antibody ACA 11

Latest Information Update: 25 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Nascent Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma
  • Preclinical Pancreatic cancer

Most Recent Events

  • 01 Jan 2018 Preclinical trials in Pancreatic cancer in USA (IV)
  • 19 Jul 2016 Nascent Biotech enters into an exclusive licensing agreement with Zhejiang Hisun Pharmaceutical Company for development, manufacture and commercialisation of pritumumab in China
  • 25 Apr 2016 Pritumumab receives Orphan Drug status for Pancreatic cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top